Smith & Nephew has agreed to buy ArthroCare for $48.25 per ArthroCare share in cash, a total consideration of approximately $1.7bn and an enterprise value of $1.5bn, as part of its strategy to strengthen its global sports medicine business.
The acquisition will be subject to customary conditions, including a vote of ArthroCare’s shareholders and governmental clearances.
Go deeper with GlobalData
Pending the satisfaction of such customary conditions, Smith & Nephew expects to close the deal in mid-2014.
The deal is expected to provide new growth opportunities for its ear, nose and throat business, enable to expand Smith & Nephew’s product range by using its minimally invasive technologies, help introduce ArthroCare’s products to new customers and markets, as well as generate additional revenue opportunities from a combined global footprint and channel presence.
In addition, Smith & Nephew expects the ArthroCare’s shoulder anchor innovation to complement its strength in knee repair, providing the company with an extensive, integrated portfolio in joint repair.
See Also:
Smith & Nephew said this deal would generate substantial cost and revenue savings, as well as enhance its new product pipeline and R&D activities.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company expects the acquisition to boost its annual profit by around $85m in the third full year after the purchase is complete.
Other opportunities include cross-selling in established sectors, expanding into new and emerging markets and maximising efficiencies across the combined business.
Smith & Nephew CEO Olivier Bohuon said: "Together, we will be able to generate significant additional revenue from the more comprehensive portfolio, combined sales force and Smith & Nephew’s global footprint.
"With this transaction, we are again accelerating our strategy to rebalance Smith & Nephew towards higher growth."
The purchase price of $48.25 per ArthroCare share will be financed from Smith & Nephew’s debt facilities and cash balances, including the existing $1bn revolving credit facility and a new two-year $1.4bn term loan underwritten by Barclays and JP Morgan.
ArthroCare president and CEO David Fitzgerald said: "The board believes that this transaction is in the best interest of our shareholders."
JP Morgan and Centerview Partners are acting as financial advisors for Smith & Nephew, while Piper Jaffray and Goldman Sachs Group are acting as financial advisors for ArthroCare.
Headquartered in Austin, Texas, US, ArthroCare has approximately 1,800 employees, including a salesforce of around 400.
In January, ArthroCare and the US Department of Justice (DOJ) entered into a Deferred Prosecution Agreement resolving the ongoing investigation by the DOJ into events under a previous management team. The investigation was first announced in December 2008.
Image: Smith and Nephew Factory from the A63, Kingston Upon Hull, East Riding of Yorkshire, UK. Photo: courtesy of Mtaylor848.
